litlas
Log inCreate account

Kenneth B. Gordon

Active 1988–2025

94
Papers
21,915
Citations
71
h-index
90
i10-index

Citations

Citations per year for Kenneth B. Gordon1989: 2 citations1990: 5 citations1992: 2 citations1994: 1 citations1995: 3 citations1996: 1 citations1997: 3 citations1998: 20 citations1999: 29 citations2000: 24 citations2001: 18 citations2002: 14 citations2003: 19 citations2004: 24 citations2005: 31 citations2006: 44 citations2007: 66 citations2008: 76 citations2009: 114 citations2010: 115 citations2011: 165 citations2012: 151 citations2013: 165 citations2014: 141 citations2015: 162 citations2016: 168 citations2017: 272 citations2018: 259 citations2019: 716 citations2020: 821 citations2021: 798 citations2022: 659 citations2023: 616 citations2024: 899 citations2025: 446 citations2026: 2 citations1991: no citations, so this year is not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,745 citing papers, 24.1% of this breakdownGermany: 572 citing papers, 7.9% of this breakdownUnited Kingdom: 530 citing papers, 7.3% of this breakdownCanada: 519 citing papers, 7.2% of this breakdownItaly: 403 citing papers, 5.6% of this breakdownChina: 362 citing papers, 5% of this breakdownFrance: 310 citing papers, 4.3% of this breakdownSpain: 260 citing papers, 3.6% of this breakdownJapan: 257 citing papers, 3.5% of this breakdownSwitzerland: 198 citing papers, 2.7% of this breakdownNetherlands: 192 citing papers, 2.6% of this breakdownDenmark: 167 citing papers, 2.3% of this breakdown
0%24.1%Other 23.9%

Institutions

Fields

  • Immunology and Microbiology56.2%
  • Medicine31.1%
  • Biochemistry, Genetics and Molecular Biology7.3%
  • Neuroscience2.6%
  • Pharmacology, Toxicology and Pharmaceutics1.2%
  • Materials Science0.4%
  • Other1.2%

Topics

  • Psoriasis: Treatment and Pathogenesis21.5%
  • Dermatology and Skin Diseases10.8%
  • Spondyloarthritis Studies and Treatments10.2%
  • Rheumatoid Arthritis Research and Therapies4.6%
  • Asthma and respiratory diseases2.5%
  • Inflammatory Bowel Disease2.4%
  • Other48%

Coauthors

All papers

Open in search
  1. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

    Authors: Alan Menter, Bruce Strober, Daniel H. Kaplan, Darío Kivelevitch, Elizabeth Farley Prater, Benjamin K. Stoff, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn Marie R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Arthur Kavanaugh, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Reena Rupani, Michael Siegel, Emily Wong, Jashin J. Wu, Vidhya Hariharan, Craig A. Elmets - Journal of the American Academy of Dermatology 2019 cited by 924

  2. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

    Authors: Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Kundu, Chitra Sekaran, Misti Linaberry, Subhashis Banerjee, Kim Papp - Journal of the American Academy of Dermatology 2022 cited by 279

  3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

    Authors: Kristian Reich, April W. Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Kenneth B. Gordon - Journal of the American Academy of Dermatology 2017 cited by 731

  4. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Authors: Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi - New England Journal of Medicine 2016 cited by 838

  5. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Authors: Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez - The Lancet 2018 cited by 662

  6. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

    Authors: Craig A. Elmets, Craig L. Leonardi, Dawn Marie R. Davis, Joel M. Gelfand, Jason Lichten, Nehal N. Mehta, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Boni E. Elewski, Kenneth B. Gordon, Alice B. Gottlieb, Daniel H. Kaplan, Arthur Kavanaugh, Darío Kivelevitch, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Henry W. Lim, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Elizabeth Farley Prater, Reena Rupani, Michael Siegel, Benjamin K. Stoff, Bruce Strober, Emily Wong, Jashin J. Wu, Vidhya Hariharan, Alan Menter - Journal of the American Academy of Dermatology 2019 cited by 486

  7. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    Authors: Kristian Reich, Kim Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Veerle Vanvoorden, Mark Lebwohl - The Lancet 2021 cited by 297

  8. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

    Authors: Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher L. Cioffi, Andrew Blauvelt - The Lancet 2021 cited by 284

  9. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Authors: Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths - Journal of the American Academy of Dermatology 2015 cited by 669

  10. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Authors: Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula - New England Journal of Medicine 2015 cited by 806

  11. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

    Authors: Kim Papp, Kenneth B. Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab Girgis, Sudeep Kundu, Subhashis Banerjee - New England Journal of Medicine 2018 cited by 414

  12. Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

    Authors: Craig A. Elmets, Neil J. Korman, Elizabeth Farley Prater, Emily Wong, Reena Rupani, Darío Kivelevitch, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn Marie R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Daniel H. Kaplan, Arthur Kavanaugh, Matthew Kiselica, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Michael Siegel, Benjamin K. Stoff, Bruce Strober, Jashin J. Wu, Vidhya Hariharan, Alan Menter - Journal of the American Academy of Dermatology 2020 cited by 329

  13. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

    Authors: Alan Menter, Joel M. Gelfand, Cody Connor, April W. Armstrong, Kelly M. Cordoro, Dawn Marie R. Davis, Boni E. Elewski, Kenneth B. Gordon, Alice B. Gottlieb, Daniel H. Kaplan, Arthur Kavanaugh, Matthew Kiselica, Darío Kivelevitch, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Elizabeth Farley Prater, Robert S. Rahimi, Reena Rupani, Michael Siegel, Benjamin K. Stoff, Bruce Strober, Elliot B. Tapper, Emily Wong, Jashin J. Wu, Vidhya Hariharan, Craig A. Elmets - Journal of the American Academy of Dermatology 2020 cited by 331

  14. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    Authors: Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon - The Lancet 2008 cited by 1,865

  15. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study

    Authors: Shikha Singla, Michael Putman, Jean W. Liew, Kenneth B. Gordon - The Lancet Rheumatology 2023 cited by 96

  16. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

    Authors: Akimichi Morita, Bruce Strober, A. David Burden, Siew Eng Choon, Milan J. Anadkat, Slaheddine Marrakchi, Tsen‐Fang Tsai, Kenneth B. Gordon, Diamant Thaçi, Min Zheng, Na Hu, Thomas Haeufel, Christian Thoma, Mark Lebwohl - The Lancet 2023 cited by 110

  17. Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*

    Authors: Kenneth B. Gordon, Mark Lebwohl, Kim Papp, H. Bachelez, Jashin J. Wu, Richard G. Langley, Andrew Blauvelt, Beth Kaplan, Megha Shah, Yiwei Zhao, Ranjeeta Sinvhal, Kristian Reich - British Journal of Dermatology 2021 cited by 99

  18. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

    Authors: Andrew Blauvelt, Kim Papp, Alice B. Gottlieb, Abel Jarell, Kristian Reich, Catherine Maari, Kenneth B. Gordon, Laura K. Ferris, Richard G. Langley, Yayoi Tada, Renata Gontijo Lima, Hany Elmaraghy, Gaia Gallo, L. Renda, S‐M. Park, Russel Burge, Jerry Bagel, the IXORA‐R Study Group, Ronald Vender, Mark Lomaga, Isabelle Delorme, Chih-ho Hong, Richard L. Langley, Lorne Albrecht, Lyn Guenther, Catherine Maari, Kim Papp, Kamal Ohson, Kirk Barber, Charles Lynde, Aditya Gupta, Leslie Rosoph, Jean‐Sébastien Gauthier, Melinda Gooderham, Norman Wasel, Mani Raman, Marni Wiseman, David Greenstein, Abel Jarell, C. A. L. Moon, Lani Clark, S. Jazayeri, Michael Bukhalo, Angela Moore, Tiffani K. Hamilton, Aron Gewirtzman, Lydie Hazan, Jeffrey Crowley, Craig Teller, Matthew Zirwas, Stacy Smith, Mark Lee, Stephen K. Tyring, Patricia Lee, Sunil Dhawan, Craig L. Leonardi, Amarilis Perez‐De Jesus, Wendy McFalda, Ellen Frankel, Paul S. Yamauchi, Scott Fretzin, Rocco Serrao, Todd Schlesinger, Scott Gottlieb, Peter Jenkin, Rola Gharib, Steven A. Davis, Navid Nami, Zoe Diana Draelos, Lloyd Godwin, Cindy E. Owen, Megan N. Landis, William Abramovits, Samuel Sanchez‐Rivera, Abby Van Voorhees, David Fivenson, Francisco A. Kerdel, Seth Forman, Jeffrey S. Weinberg, José González-Chávez, Brent Boyce, Linda Stein‐Gold, Charles P. Hudson, Constance Brown, James Coggi, Christina Feser, Rion Forconi, Sandra Johnson, Mark McCune, Lawrence Green, Vandana Madkan, Dana Maxwell Shipp, Kenneth B. Gordon, Jill Waibel, Oscar Soto‐Raices, Jennifer Cather, Scott Miller, John P. Scott, Douglas Young, Jessica Kaffenberger and 42 more - British Journal of Dermatology 2019 cited by 172

  19. Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*

    Authors: Kristian Reich, Kenneth B. Gordon, Bruce Strober, April W. Armstrong, Megan Miller, Yaung‐Kaung Shen, Yin You, Chenglong Han, Ya‐Wen Yang, Peter Foley, C.E.M. Griffiths - British Journal of Dermatology 2021 cited by 81

  20. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

    Authors: Gerd R Burmester, Remo Panaccione, Kenneth B. Gordon, M. McIlraith, Ana P. Lacerda - Annals of the Rheumatic Diseases 2012 cited by 586

  21. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Authors: Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp - Journal of the American Academy of Dermatology 2007 cited by 883

  22. Guidelines of care for the management of psoriasis and psoriatic arthritis

    Authors: Alan Menter, Neil J. Korman, Craig A. Elmets, Steven R. Feldman, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, John Koo, Mark Lebwohl, Craig L. Leonardi, Henry W. Lim, Abby S. Van Voorhees, Karl R. Beutner, Caitriona Ryan, Reva Bhushan - Journal of the American Academy of Dermatology 2011 cited by 454

  23. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

    Authors: Richard G. Langley, Steven R. Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu, Jean-Paul Ortonne, Kenneth B. Gordon, Alexa B. Kimball - Journal of the American Academy of Dermatology 2010 cited by 216

  24. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

    Authors: Craig A. Elmets, Henry W. Lim, Benjamin K. Stoff, Cody Connor, Kelly M. Cordoro, Mark Lebwohl, April W. Armstrong, Dawn Marie R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Daniel H. Kaplan, Arthur Kavanaugh, Matthew Kiselica, Darío Kivelevitch, Neil J. Korman, Daniela Kroshinsky, Craig L. Leonardi, Jason Lichten, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Elizabeth A. Farley Prater, Reena Rupani, Michael Siegel, Bruce Strober, Emily Wong, Jashin J. Wu, Vidhya Hariharan, Alan Menter - Journal of the American Academy of Dermatology 2019 cited by 190